Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 500 participants.

Also called NCT05410860

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 500 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05410860
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05410860. Randomized; triple masking; primary purpose treatment. Start 2022-06-30 (actual); primary completion 2024-08-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
Condition
Tachycardia, Supraventricular
Condition
Paroxysmal Supraventricular Tachycardia
Intervention (Drug)
Etripamil NS 70 mg
Intervention (Drug)
Placebo
Lead sponsor
Corxel Pharmaceuticals (class: industry)
Collaborator
Milestone Pharmaceuticals Inc. (class: other)

Record details

Record id
cardio:ct-nct05410860
Content hash
59ba39b70df69698d3686afa959940aefd128935399e82115df76988c42b530b